LH Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Labcorp Holdings (NYSE: LH)
›
Labcorp Holdings (NYSE: LH) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 71,000 employees.
The shares were at 370.23 USD on 20 November 2026, up 41.9% over 52 weeks. Its 52-week range is 245.00 USD to 375.10 USD: the price is 1.3% below the high and 51.1% above the low.
At a market capitalisation of 29.95B USD, it trades at 30.2 times trailing earnings and 18.8 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 15% for LH. It pays a dividend yielding 0.78% (it pays out 24% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
Labcorp Holdings reports return on equity of 10.2%, an operating margin of 11.2% and revenue up 6.9% year over year.
Its debt exceeds its cash by 6.59B USD, a debt-to-equity ratio of 0.76. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 16 analysts cover the stock, with an average rating of Buy; their mean price target of 390.06 USD is 5.4% above the current price. The next earnings report is expected on 23 February 2027.